Sanofi is a French multinational pharmaceutical company founded in 1973 as a subsidiary of Elf Aquitaine. Over decades, it grew through strategic mergers and acquisitions, becoming a global leader in vaccines, rare diseases, and consumer healthcare.
Sanofi is established as a wholly owned subsidiary of the French oil company Elf Aquitaine, focusing on pharmaceuticals and cosmetics. #corporate #history
Sanofi launches Ticlid, an antiplatelet drug used to prevent strokes. It becomes a blockbuster and establishes Sanofi's cardiovascular franchise. #pharma #innovation
Sanofi begins building its vaccine and diagnostics portfolio through acquisitions and internal R&D, laying groundwork for Sanofi Pasteur. #vaccines #expansion
Sanofi partners with Bristol-Myers Squibb to co-market Plavix, a blood thinner that becomes one of the world's best-selling drugs. #partnership #blockbuster
Sanofi goes public, listing on the Paris Bourse, raising capital for expansion and reducing dependence on parent company Elf Aquitaine. #finance #ipo
Sanofi acquires Synthelabo, a French pharmaceutical company, merging to form Sanofi-Synthelabo, strengthening its CNS and cardiovascular pipelines. #merger #pharma
Sanofi markets Lovenox, a low-molecular-weight heparin, which becomes a leading anticoagulant globally. #pharma #anticoagulant
Sanofi-Synthelabo acquires Aventis in a $64 billion hostile takeover, forming Sanofi-Aventis, the world's third-largest pharmaceutical company. #merger #bigpharma
Sanofi acquires Zentiva, a Czech generics company, expanding its presence in Central and Eastern Europe. #generics #expansion
Sanofi launches Apidra, a rapid-acting insulin analog, strengthening its diabetes franchise. #diabetes #pharma
Sanofi acquires Acambis, a British vaccine developer, boosting its vaccine pipeline, particularly for smallpox and other infectious diseases. #vaccines #acquisition
Sanofi acquires the rights to Symbicort, an asthma/COPD drug, in some markets, expanding its respiratory portfolio. #respiratory #pharma
Sanofi acquires Chattem, a US consumer health company, adding brands like IcyHot and Gold Bond, boosting OTC presence in North America. #consumerhealth #acquisition
Sanofi acquires Genzyme for $20 billion, gaining a leading position in rare diseases and multiple sclerosis drug Aubagio. #raredisease #biotech
Sanofi launches Multaq, an antiarrhythmic drug, though later faces safety concerns and declining sales. #cardiology #pharma
Sanofi reorganizes into five global business units: Sanofi Pasteur (vaccines), Genzyme (rare diseases), Sanofi Diabetes, Sanofi Consumer Health, and Sanofi Generics. #corporate #restructuring
Sanofi launches Toujeo, a longer-acting insulin for diabetes, aiming to compete with Lantus and newer insulins. #diabetes #pharma
Sanofi acquires Merial, the animal health unit of Boehringer Ingelheim, but later spins it off as part of a broader animal health consolidation. #animalhealth #acquisition
Sanofi and Regeneron launch Praluent, a PCSK9 inhibitor for cholesterol management, facing competition from Amgen's Repatha. #cardiovascular #biotech
Sanofi attempts to acquire Medivation, a US cancer drug maker, but loses to Pfizer. #M&A #cancer
Sanofi and Regeneron launch Dupixent for atopic dermatitis and asthma, which becomes a blockbuster with approvals for multiple inflammatory diseases. #immunology #biotech
Sanofi acquires Ablynx for $4.8 billion, gaining access to its Nanobody platform and caplacizumab for rare blood disorder. #biotech #nanobodies
Sanofi acquires Bioverativ for $11.6 billion, adding hemophilia drugs Eloctate and Alprolix, strengthening its rare disease portfolio. #raredisease #hemophilia
Sanofi acquires Principia Biopharma for $3.4 billion, adding BTK inhibitors for multiple sclerosis and other autoimmune diseases. #autoimmune #acquisition
Sanofi launches Cablivi, the first Nanobody-based drug, for acquired thrombotic thrombocytopenic purpura (aTTP). #raredisease #innovation
Paul Hudson, formerly of Novartis, becomes CEO, initiating a 'Road to 2025' strategy focusing on innovation and growth platforms. #leadership #corporate )
Sanofi acquires Kiadis Pharma for $308 million, gaining access to its natural killer cell therapy platform for oncology. #celltherapy #oncology
Sanofi partners with Translate Bio to develop an mRNA COVID-19 vaccine, but faces delays and ultimately does not succeed in the market. #covid19 #vaccine
Sanofi acquires Tidal Therapeutics, gaining access to its in vivo mRNA technology for immune-modulating therapies. #mRNA #innovation
Sanofi sells its European generics business (Zentiva) to Aurobindo Pharma for $2 billion, focusing on core innovative medicines. #divestiture #generics
Sanofi and Regeneron receive FDA approval for Evkeeza, an angiopoietin-like 3 inhibitor for homozygous familial hypercholesterolemia. #cardiovascular #raredisease
Sanofi acquires Kadmon Holdings for $1.9 billion, adding belumosudil for chronic graft-versus-host disease and a portfolio in liver diseases. #raredisease #transplant
Sanofi launches Xenpozyme, an enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD), a rare lysosomal disorder. #raredisease #enzymereplacement
Sanofi acquires Amunix Pharmaceuticals for $1 billion, gaining its Probody platform for conditionally activated cancer therapeutics. #oncology #biotech
Sanofi collaborates with Scribe Therapeutics, investing $25 million upfront and potential milestones, for CRISPR-based therapies in oncology. #crispr #geneediting
Sanofi announces sale of its consumer health division to Clayton, Dubilier & Rice for roughly $16 billion, focusing on pharmaceuticals and vaccines. #divestiture #consumerhealth
Paul Hudson is appointed Chairman of the Board, solidifying his leadership as Sanofi continues its transformation. #leadership #governance )
Sanofi launches Altuviiio, a factor VIII replacement therapy with extended half-life for hemophilia A, improving prophylaxis. #hemophilia #innovation
Sanofi launches Valenzza (difelikefalin) for pruritus in chronic kidney disease, expanding its specialty care portfolio. #nephrology #pharma
Sanofi acquires Inhibrx for $1.8 billion, adding a pipeline of rare disease therapies including an alpha-1 antitrypsin deficiency treatment. #raredisease #acquisition
Sanofi receives expanded FDA approval for Sarclisa in combination with carfilzomib and dexamethasone for relapsed multiple myeloma. #oncology #myeloma
Sanofi completes the spin-off of its consumer health business into a standalone company, Opella, marking a strategic shift to pure-play biopharma. #restructuring #corporate
Sanofi acquires global rights to Nimbus' TYK2 inhibitor for autoimmune diseases in a $4 billion deal, strengthening immunology pipeline. #autoimmune #acquisition